Genentech expands Holly Springs project to $2B for GLP-1, 500-plus jobs

Genentech announced an expansion of its planned Holly Springs manufacturing project that raises the investment to roughly $2 billion and increases the planned workforce to more than 500 people. The company said the enlarged facility will support development and manufacturing related to obesity drug candidates in the GLP-1 class and is expected to be operational by the end of 2029.

The updated plan represents a sizable jump from an earlier $700 million proposal and adds about 100 positions on top of previously announced hiring. State and local incentives for the project were approved earlier and remain part of the development framework. Genentech executives and state officials emphasized the project's expected economic impact and job quality as part of the announcement.

For Wake County and Holly Springs, the expansion anchors the town more firmly in the Triangle's life‑sciences corridor. The increase in capital spending will drive a multi‑year construction cycle and create demand for local suppliers, professional services, and technicians. A facility focused on GLP-1 development places Holly Springs on the map for next‑generation biomanufacturing concentrated on obesity and metabolic medicines, sectors that have attracted outsized capital over the past several years.

The jobs included in the headcount are likely to be a mix of manufacturing, technical, and professional roles. That mix tends to produce higher average wages than many other local industries and can expand the tax base, but it also creates near‑term pressures on housing, transportation, and workforce training. Local governments and workforce development partners will need to coordinate to match hiring timelines and skills pipelines, since the facility is not expected to be operational until late 2029.

This announcement arrives amid a broader trend of life‑sciences investment across the Research Triangle, where municipalities have competed to build out infrastructure and incentives to capture biotech and biomanufacturing projects. Holly Springs has increasingly marketed itself as a practical site for large-scale biomanufacturing, with available land and proximity to research institutions and skilled labor pools in Wake County.

For residents, the immediate effects will appear in construction activity and planning conversations; over the medium term, the project promises higher‑paying jobs and a stronger tax base. The critical next steps will be aligning local infrastructure and workforce training with Genentech's construction and hiring schedule so the economic benefits come to Wake County as the facility moves toward its 2029 operational target.